aTyr Pharma (LIFE)
(Real Time Quote from BATS)
$1.60 USD
0.00 (0.00%)
Updated May 3, 2024 02:30 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LIFE 1.60 0.00(0.00%)
Will LIFE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LIFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LIFE
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
5 Top Stocks to Play Earnings Beat Potential
LIFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)
5 Top Stocks Likely to Top Earnings Estimates
Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates
Other News for LIFE
Piper Sandler Reaffirms Their Buy Rating on aTyr Pharma (LIFE)
RBC Capital Sticks to Their Buy Rating for aTyr Pharma (LIFE)
Strong Buy Rating for aTyr Pharma as Efzofitimod Shows Promise and Financial Stability
Atyr Pharma: Q1 Earnings Snapshot
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update